

List of Tables & Figures

<u>Tables</u>		Page No.
Table 1:	Composition of high fat diet	35
Table 2:	List of primers for real time PCR	45

<u>Figures</u>		Page No.
Figure 1:	Types of liver diseases	2
Figure 2:	Reversible and non-reversible stages of nonalcoholic fatty liver disease (NAFLD)	3
Figure 3:	Continent-wise prevalence of NAFLD in the year 2019	4
Figure 4:	Association of metabolic syndrome components with nonalcoholic steatohepatitis (NASH)	6
Figure 5:	The “two-hit” hypothesis in the progression of Nonalcoholic fatty liver disease (NAFLD) to Nonalcoholic steatohepatitis (NASH)	7
Figure 6:	The Liver-gut-brain axis	8
Figure 7:	The liver-brain crosstalk in the condition of lifestyle disorder	10
Figure 8:	Types of Biological rhythms	13
Figure 9:	Circadian rhythms in daily physiological functions	14
Figure 10:	Molecular mechanism of circadian clock	15
Figure 11:	Circadian clock mediated control and coordination of metabolic functions of liver	17
Figure 12:	Chronodisruption mediated perturbations in psychiatric and metabolic pathologies	21
Figure 13:	Alterations in neuro-behavior due to psychosocial and physiological stress	22
Figure 14:	Protective role of melatonin on various organs	23
Figure M1:	Schematic representation of normal and altered photoperiodic regime to induce chronodisruption	33

Figure 1.1:	Flow chart of experimental protocol followed for validation of experimentally induced Nonalcoholic steatohepatitis	50
Figure 1.2:	Viscera showing adiposity build up in experimental mice	55
Figure 1.3:	Body and liver weight in mice subjected to (H) diet and/or (CD) induced photoperiodic manipulation	56
Figure 1.4:	Visceral adipose tissue weight and body circumference in experimental mice	57
Figure 1.5:	Food and water intake in experimental groups	58
Figure 1.6:	Melatonin treatment improves liver function in H and/or CD subjected mice	59
Figure 1.7:	Melatonin treatment improves serum lipid profile in H and/or CD subjected mice	60
Figure 1.8a:	Histological examination of liver done by H&E staining of H and/or CD exposed group showing improvement in melatonin treatment (100X)	61
Figure 1.8b:	Histological examination of liver done by H&E staining of H and/or CD exposed group showing improvement in melatonin treatment (400X)	62
Figure 1.9:	Effects of H and/or CD subjected mice on serum protein concentrations	63
Figure 1.10:	CD and/or H diet alters the expression of hepatic core circadian clock genes as evidenced by their mRNA profiles	64
Figure 1.11:	Altered serum melatonin rhythmicity in mice subjected to CD and/or H diet	65
Figure 1.12:	CD and/or H diet alters the expression of hepatic lipid regulatory genes as evidenced by their mRNA profiles	66
Figure 2.1:	Schematic representation of experimental protocol followed for inflammatory changes in liver and brain following induction of NASH	76
Figure 2.2:	Alterations in circulating inflammatory cytokines in mice	79

	subjected to (H) diet and/or subjected to CD	
Figure 2.3:	Effect of melatonin on genes regulating inflammation (TNF- α , IL-1 β , IL-6 and MCP-1) in (H) and/or CD exposed mice liver	80
Figure 2.4:	Altered mRNA of pro-inflammatory (NF κ B, IL-12 and IL-17) and anti-inflammatory (IL-4 & IL-10) marker genes in mice subjected to (H) and/or CD	81
Figure 2.5:	Heat map analysis of pro- and anti-inflammatory gene expression in the liver	82
Figure 2.6:	Effect of melatonin on genes regulating inflammation (TNF- α , IL-1 β , IL-6 and MCP-1) in (H) and/or CD exposed mice hippocampus	83
Figure 2.7:	Altered mRNA expression of (CREB, IBA-1, NF- κ B, IL-12 and IL-17) in hippocampus of mice subjected to CD and/or (H) diet	84
Figure 2.8:	Effect of melatonin on anti-inflammatory marker (IL-4 & IL-10) genes in hippocampus of subjected to CD and/or (H) diet	85
Figure 2.9:	Heat map analysis of pro- and anti-inflammatory gene expression in the hippocampus	86
Figure 2.10:	Altered serum corticosterone levels in mice subjected to CD and/or H diet	87
Figure 3.1:	Experimental design for 16s rRNA metagenomic analysis of gut microbiota	96
Figure 3.2:	The percentage relative abundance of identified gut microbiota in mice subjected to (CD) and exogenous melatonin treated (CDM) group	99
Figure 3.3:	The percentage relative abundance of identified gut microbiota in mice subjected to (H) and exogenous melatonin treated (HM) group	100
Figure 3.4:	The percentage relative abundance of identified gut microbiota in mice subjected to (HCD) and exogenous	101

	melatonin treated (HCDM) group	
Figure 3.5:	Rarefaction curves of microbial clusters in fecal samples of different experimental groups	102
Figure 3.6:	The species diversity and richness indices of the gut microbiome in the faecal sample of experimental groups	103
Figure 3.7:	Stacked bar chart of relative abundance of the gut microbiota in faecal samples experimental mice subjected to (H) diet and/or (CD)	104
Figure 3.8:	Heat map showing the relative abundances and distribution of representative 16S rRNA gene tag sequences classified at the genus level	105
Figure 3.9:	Corrective changes by melatonin treatment in abundance of Firmicutes and Bacteroidetes (F/B ratio) of experimental mice subjected to (H) diet and/or (CD)	106
Figure 3.10:	Alterations in the abundance of Ruminococcaceae and Desulfovibrionales in faecal samples of experimental mice subjected to (H) diet and/or (CD)	107
Figure 3.11:	Alterations in the relative abundance of genus Alistipes, Helicobacter and Mucispirillum in faecal samples of experimental mice subjected to (H) diet and/or (CD)	108
Figure 3.12:	Positive correlation between the physical characters (body and liver weight)and F/B ratio	109
Figure 3.13:	Correlation between the physical characters (body circumference and visceral adipose tissue weight)and F/B ratio	110
Figure 3.14:	Correlation between the NASH histology (steatosis and ballooning score) and F/B ratio	111
Figure 4.1:	Experimental design for neuro-behavioral analysis in mice subjected to CD and (H) fed mice	120
Figure 4.2:	Locomotor counts (10 min) using infrared actimeter in diurnal and nocturnal regime	125
Figure 4.3:	Head dipping counts in Hole board test in diurnal and	126

	nocturnal regime	
Figure 4.4:	Anxiety-like behavior tested using marble burying in diurnal and nocturnal experiments	127
Figure 4.5:	Total number of marbles buried (n) at different intervals of 10, 20 and 30 minutes in diurnal experiment	128
Figure 4.6:	Total number of marbles buried (n) at different intervals of 10, 20 and 30 minutes in nocturnal experiment	129
Figure 4.7:	Number of entries in elevated plus maze test in diurnal and nocturnal regime	130
Figure 4.8:	Time spent (s) in elevated plus maze test in diurnal and nocturnal regime	131
Figure 4.9:	Tracking images of mice performance in elevated plus maze in diurnal and nocturnal regime	132
Figure 4.10:	Immobility time in forced swim test in diurnal and nocturnal regime	133
Figure 4.11:	Immobility time in tail suspension test in diurnal and nocturnal regime	134
Figure 4.12:	Sucrose preference test to measure depression and/or anhedonia behavior in experimental groups	135
Figure 4.13:	Time spent (s) and distance travelled (m) in morris water maze test in diurnal and nocturnal regime	136
Figure 4.14:	Number of entries in the platform zone in morris water maze in diurnal and nocturnal regime	137
Figure 4.15:	Tracking images of mice movement in the morris water maze test during the probe trial	138
Figure 5.1:	Experimental protocol followed for hepatic-hippocampal crosstalk	148
Figure 5.2:	Serum bilirubin profile in different experimental groups	152
Figure 5.3:	Altered hepatic mRNA expression of bile acid metabolism genes	153
Figure 5.4:	Altered hepatic mRNA expression of bile acid transporter	154

	genes	
Figure 5.5:	Effect of melatonin on genes regulating BDNF-TrkB pathway in hippocampus	155
Figure 5.6:	Altered hippocampal mRNA expression of neurotrophins	156
Figure 5.7:	Protein expression of BDNF-TrkB pathway	157
Figure 5.8:	Alterations in thyroid hormones in mice subjected to (H) diet and/or (CD)	158